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1. IntroductIon
Organophosphorous compounds (OPCs) are the group 
of phosphorus containing organic derivatives which have 
been largely used as pesticides and insecticides in agricultural 
including chemical warfare agents (CWA) in terrorists 
attacks1. OPC causes fatality in acute poisoning and also have 
long term complications due to their inhibitory action on 
acetylcholinesterase enzyme (AChE)2. For the management of 
OP poisoning, available therapeutic regimen includes atropine 
(anti-muscaranic), oximes (AChE reactivator) and diazepam 
(anti- convulsant)3-5. Pralidoxime (2-PAM), obidoxime and 
HI-6 oximes are currently used against acute poisoning of OP/
nerve agent but their unequal efficacy against the entire nerve 
agent raises the ambiguity on the broad antidotal efficacy of 
these oximes. Thus, search for a new, efficacious, least toxic 
AChE reactivator oxime is the standing goal of the researcher 
since long run. 
For the development of a new compound and its usage 
as a drug, its toxicology study is the basic requirement. 
The pharmacological profiles of oximes have been widely 
studied but there is dearth of studies available concerning to 
preclinical toxicology. The toxicity of HI-6 is least in reference 
to cytotoxicty, genotoxicity6 and LD50 in comparison to other 
oximes. But the only drawback is its instability in aqueous 
solution7. Hence, in search of an efficacious, least toxic 
and stable AChE reactivator, new HNK series oximes (bis-
pyridinium derivatives of 2-(hydroxyimino)-N-(pyridin-3-yl)
acetamide) have been synthesised in this establishment.
Having shown better in vivo antidotal efficacy against 
Diisopropylphosphoroflouridate (DFP) and sarin poisoning8, 
9, the present study aims to investigate in vitro cytotoxicity 
study and in vivo acute toxicity of HNK series oximes in 
comparison to 2-PAM. Different Human cell lines were used 
(Hela, HepG2, and HEK 293) for cytotoxicity studies. For LD50 
determination, the toxicity of these compounds (HNK series) 
was compared by determining LD50 using intramuscular (i.m.), 
intra-peritoneal (i.p.), oral (p.o.) and intravenous (i.v.) routes 
of administration in Swiss albino male mice.
2. MaterIals and Methods
2.1 chemicals
Oximes: 1,1’-(ethane-1,2-diyl) bis(3-(2-(hydroxyimino) 
acetamido) pyridinium) dibromide (HNK-102); 1,1’-(hexane-
1,6-diyl) bis(3-(2-(hydroxyimino)acetamido)pyridinium) 
dibromide (HNK-106); 1,1’-(1,4-phenylene bis(methylene) 
bis(3-(hydroxyimino) acetamido) pyridinium) dibromide 
(HNK-111) (as shown in Fig. 1) were synthesised in this 
establishment with > 98 per cent purity (NMR)10. Pralidoxime 
chloride (IP) obtained from Kwality Pharma, India. Dulbecco 
MEM media, FBS and standard 3-(4,5-dimethylthiazole)-
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2,5diphenyltetraazolium bromide (MTT) reagent were 
procured from Sigma Chemicals Co. (St. Louis Mo). 
Kg of body weight (Gad and Weil)11. For LD50 determination, 
scales of doses were taken in logarithm with four animals for 
each dose. The LD50 value was then calculated using formula: 
Log m = log D + df. where m = median effective dose, D = 
lowest dose, f = table value from Gad and Weil11.
All the oximes were diluted in freshly prepared mixture 
solution of normal saline (sodium chloride 0.9 per cent in 
distilled water) and propylene glycol in a ratio of 9:1, v/v, 
respectively and used in the entire study as solvent for all 
injections8. Intramuscular administration of oximes was carried 
out in lateral thigh muscles of mice at angle of 45°.
Oral administration (gavage) was done using a 20-gauge 
oral feeding cannula (Harvard Apparatus). Oximes were 
administered intravenously by pre dilating the tail vein in 
warm water (40 °C - 45 °C) for 5 min - 7 min using 27 gauge 
needles.
Intraperitoneal injections were given using 24 gauge 
needles into the peritoneal cavity of the mice. Volume of all 
injections was kept between 0.1 mL - 0.2 mL. The animals were 
observed for ensuing mortality up to 14 days, post exposure of 
oximes.
2.6 statistical analysis
Results are expressed as mean±SEM. Data were analysed 
by one-way ANOVA followed by Dunnett test and Student‘t’ 
test. Level of p < 0.05 was considered significant.
3. results
3.1 cytotoxicity assay
Cytotoxicity assay was done to establish the toxicity 
and maximum tolerated dose of HNK series of oximes as 
compared to 2-PAM. Cells were treated with wide range of 
doses of oximes (5 mg/mL to 0.5 ng/mL) except HNK-102 
which was not soluble beyond 0.5mg/mL in aqueous media. 
In Hela cells, at 5 mg/mL concentration 2-PAM, HNK-106 
and HNK-111 showed 50 ± 7 %, 45 ± 7 % and 45 ± 3 % cell 
survival respectively as compared to control. At 0.5 mg/mL 
HNK-106(69 ± 1.2 % cell survival) and HNK-111(71 ± 4 
% cell survival) induced significant toxicity as compared to 
2-PAM (90 ± 2 %), while HNK-102 (83 ± 4 %) is equally 
safe as 2-PAM. A dose response cytotoxic effect of oximes in 
Hela cells were determined by MTT assay. Cells were plated 
on to a 96 well and treated with varying concentration of 
oximes for 24 h as shown in Fig. 2. In Hep G2 cells at 5mg/
mLconcentration HNK-106 showed highest toxicity with 
28±4% cell survival followed by 2-PAM (40 ± 4 %) and HNK-
111(56 ± 3 %). At 0.5mg/mL HNK-102 (93 ± 3 %), offered 
least toxicity as compared to 2-PAM (79 ± 8 %), HNK-106 (63 
± 2 %) and HNK-111(71 ± 7 %). A dose response cytotoxic 
effect of oximes in Hep-G2 cells were determined by MTT 
assay. Cells were plated on to a 96 well and treated with 
varying concentration of oximes for 24 h as shown in Fig. 3. 
In HEK-293 cells at 5 mg/mL HNK-111 offered maximum cell 
protection with 71 ± 1 % cell survival as compared to HNK-
106 (64 ± 1 %) and 2-PAM (59 ± 2 %). At 0.5 mg/mL PAM 
(100 ± 4 %) and HNK-102(122 ± 2 %) are equally safe as 
compared to HNK-106 (64±3.3 %) and HNK-111(84 ± 3 %). 
A dose response cytotoxic effect of oximes in HEK293 cells 
Figure 1. structure of Bis-quaternary 2-(hydroxyimino)-N-
(pyridin-3-yl) acetamide derivatives.
2.2 cell lines
Three malignant Human cell lines: Human cervix 
adenocarcinoma (Hela, epithelial), Human Caucasian 
hepatocyte carcinoma (Hep G2, epithelial), Human embryonic 
Kidney (HEK 293, epithelial) were obtained from national 
centre for cell sciences (NCCS), Pune, India. Cells were 
maintained in DMEM (high glucose) supplemented with 10 
per cent heat inactivated Fetal Bovine Serum (FBS), 100 U/mL 
penicillin, 100 µg/mL streptomycin and 2 mM glutamine at 
37 оC in a humidified atmosphere containing 5 per cent CO2 
and 95 per cent air in incubator.
2.3 cell Viability assay  
The concentration of oximes that is toxic to the cells was 
determined from the plots of viability of cells by MTT assay. 
Cells were dispensed in 96-well flat bottomed micro titer 
plates (NUNC, Rosklide, Denmark) at a density of Hela (2 × 
105), Hep-G2 (1 × 105) and HEK- 293 (1 × 105) cells / well. 
Cells were incubated with broad range of oxime concentration 
starting from 5 mg/mL to 0.5 mg/mL with tenfold dilution. 
After 24 h of incubation, 0.5 mg/mL MTT in DMEM medium 
was added to the cells and incubated for 4 h. The resulting 
formazan crystals were dissolved in dimethyl sulfoxide. The 
absorbance was measured using an ELISA reader (Chameleon 
Multi-detection Platform, Finland) at a wavelength of 570 nm. 
Each experiment was done in quadruplicate and concentration 
of the oximes that is 50 per cent toxic to the cell (CC50) was 
determined by regression analysis.
2.4 animals
Randomised out-bred male Swiss albino mice (Animal 
House, DRDE, Gwalior, India) weighing 25 g - 30 g were used 
for the study. Four mice were housed in each cage. Dust free 
steam autoclaved paddy husk was used as bedding material. 
The cages were maintained in environmentally controlled 
room (25 ± 2 ºC, RH 40 % - 60 %). For all the experiments, 
maximum four mice per dose were used. The 3Rs (Replace, 
Reduce and Refine) of animal’s ethics were strictly followed. 
Prior approval was obtained for use of animals by Institutional 
Animal Ethics Committee (IAEC); a statutory committee 
constituted by Committee for Purpose of Control and 
Supervision of Experiments on Animals (CPCSEA), Animal 
Welfare Cell, Ministry of Environment, Forests and Climatic 
change, Government of India.
2.5 ld50 determination
Median lethal dose (LD50) of oxime was determined 
following ‘moving average’ method and expressed as mg/
151
SWAMI, et al.: DEF. LIFE SCI. J., VOL. 1, NO. 2, SEPTEMBER 2016, DOI : 10.14429/dlsj.1.10733
were determined by MTT assay. Cells were plated on to a 96 
well and treated with varying concentration of oximes for 24 
h as shown in Fig. 4. At 5 mg/mL HNK-111 offered least or 
comparable toxicity to 2-PAM, while At 0.5 mg/mL HNK-102 
was found to be better than other oximes. The concentration of 
oximes that is toxic to 50 % (CC50) of the cells was determined 
from the plots of viability of cells by MTT assay. In Hela cell 
lines CC50 of 2-PAM (4.15 mg/mL) and HNK-102 (> 5mg/mL) 
was comparable and marginally higher than CC50 of HNK-106 
(3.9 mg/mL) and HNK-111 (3.9 mg/mL). In Hep G2 cells CC50 
of 2-PAM, HNK-102, HNK-106 was found to be 4.0 mg/mL, 
> 5 mg/mL, 3.3 mg/mL, and 4.7 mg/mL, respectively. Since 
HNK 102 was soluble up to 0.5 mg/mL for calculation of CC50 
of HNK 102 data was extrapolated. In HEK-293 cells CC50 was 
calculated as: 2-PAM (> 5 mg/mL), HNK-106 (4.61 mg/mL) 
and HNK-111(> 5 mg/mL) respectively. Parallel to this, HNK-
102 oxime did not show any cytotoxicityin HEK 293 cells at 
0.5 mg/mL dose and lower. Further phase contrast microscopic 
observation of cell treated with same doses of oximes, also 
showed dose-dependent morphological alterations. Similar 
to cell viability assays at 5mg/mL of oxime treatment, cells 
showed the visible change in the cell morphology with relative 
reduction in cell size and condensation of cellular material (as 
shown in Figs. 5 (a), (b), (c)). Lower doses of oxime did not 
bring any change in cellular morphology. 
3.2 signs of toxicity by oximes
The clinical signs and symptoms were observed in 
Swiss mice following 1.0 LD50 dose of oxime exposure. The 
mice treated with 1.0 LD50 dose of oxime showed bout of 
convulsions, tremors, dyspnea and were culminated in death. 
The animals did not show noticeable signs of toxicity when 
exposed to sub lethal doses of oximes.
3.3 In Vivo toxicity of oximes through different 
routes
LD50 values of oximes (mg/Kg) through different route are 
given in Table 1. Through intramuscular route HNK-106 and 
HNK-111 was found to be most toxic (LD50 = 35.35 mg/Kg)
8. 
HNK-102 was least toxic having shown 282.8 mg/Kg LD50 
values8, compared to 2-PAM (180 mg/Kg)12. Similarly, HNK-
102 showed least toxicity (407 mg/Kg) through intraperitonial 
route, compared to 2-PAM, HNK-106 and HNK-111(141.14 
mg/Kg, 28.28 mg/Kg, 14.14 mg/Kg).When given orally, 
2-PAM was found least toxic among all the oximes, having 
2520 mg/Kg LD50 value. HNK-102, HNK-106 and HNK-111 
showed LD50 as 1131.3 mg/Kg, 1600 mg/Kg, > 565 mg/Kg, 
respectively.
Figure 2. cytotoxicty of oximes: the 50 % cytotoxic concentration 
(cc50) was calculated by regression analysis. 2-PaM; 
Y = -26.31x + 159.2; r2 = 0.901; cc50 = 4.15 mg/ml; 
hnK-102, Y = -12.66x + 115.2; r2 = 1; cc50 = >5 
mg/ml; hnK-106, Y = - 20.41x + 130.4; r2 = 0.948; 
cc50 = 3.93 mg/ml; hnK-111, Y = - 17.56x + 120.2; 
r2 = 0.934; cc50 = 3.99 mg/ml. data are the mean 
± seM of four independent experiments each in 
quadruplicate. 2-PaM showed 90 % viability at 0.5 
mg/ml dose; #p < 0.01 compared to hnK-106 and 
hnK-111.
Figure 3. cytotoxicty of oximes: the 50 % cytotoxic concentration 
(cc50) was calculated by regression analysis. 2-PaM, 
Y = - 16.83x + 117.9; r2 = 0.784; cc50 = 4.03 mg/ml; 
hnK-106, Y = - 23.34x + 127.4, r2 = 0.944; cc50 = 
3.316 mg/ml; hnK-111, Y = - 11.43x + 104.0, r2 = 
0.973; cc50 = 4.72 mg/ml; hnK-102, Y = - 4.148x + 
106.8, r2= 0.854, cc50 > 5 mg/ml. hnK-102 showed 
93 % viability at 0.5 mg/ml doses; #p<0.001compared 
to 2-PaM.
Figure 4. cytotoxicty of oximes: the 50 % cytotoxic concentration 
(cc50) was calculated by regression analysis. 2-PaM, 
Y = - 14.55x + 124.8, r2 = 0.859; cc50 > 5 mg/ml; 
hnK-106, Y = -15.13x + 119.9, r2 = 0.871; cc50 = 4.61 
mg/ml; hnK-111, Y = - 15.45x + 131.5, r2 = 0.9987, 
cc50 > 5 mg/ml.
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4. dIscussIon
The choice of antidotal treatment against acute poisoning 
of OP compounds is a serious problem and to protect the 
exposed victims of acute poisoning is a big challenge for 
the researchers. The veterans are trying to counteract the 
OP poisoning either by increasing the efficacy of antidotes 
(post exposure treatment) or by developing a more effective 
Acetylcholinesterase (AChE) enzyme reactivator (oximes). 
But the failure of oximes against wide OP compounds is due 
to absence of optimal concentration of oximes in the body, 
post OP exposure13. Moreover the delay in the treatment with 
oxime therapy also leads to inefficient medical treatment 
against OP poisoning14. Along with aforesaid issues, problems 
like stability, intrinsic toxicity, solubility and broad spectrum 
efficacy against all OPs urge the need for a better AChE 
reactivator in a therapeutic regimen. In the light of this view, 
the novel bis-pyridinium acetamide derivatives (HNK oximes) 
were synthesised and their antidotal efficacy was evaluated 
against acute poisoning of DFP and sarin8,9. Showing better 
efficacy in terms of protection and AChE reactivation, further 
oximes were evaluated for their toxicity study in comparison 
to established 2-PAM oxime. Herein, the study reports the 
toxicity of new HNK series oximes using in vitro and in vivo 
approach in different human cell lines and Swiss male mice.
Evaluation of the inherent toxicity of the oximes is one of 
the major prerequisite for the development of newly synthesised 
oximes as a drug. In vitro toxicity of oximes was analysed in 
three human cell lines using broad range of concentration from 
5 mg/mL to 0.5 ng/mL to observe the maximum tolerated dose 
and CC50 of HNK series of oximes, in comparison to 2-PAM. 
Three cell lines were chosen for this study to represent a broad 
range of origin of tissues. HEK 293, HepG2 and Hela cell lines 
were arose from cervical tissue, liver and kidney respectively. 
Generally, for studying the basal cytotoxicity such as cell growth 
and viability, epithelial cell lines Hela are used. Presence of 
enzymes relevant to xenobiotic metabolism makes HepG2 cell 
line a suitable model to study oxime efficacy. The selection of 
HEK 293 cells in oxime toxicity referred due to the presence of 
Acetylcholine receptors on these cells. The oxime having direct 
effect on these receptors in OP toxicity, hence these cells can 
be better subject to study the dose dependent oxime toxicity. 
Determination of maximum tolerated dose and CC50 of the 
drug candidate will give better idea for its therapeutic index. 
Observing maximum safe dose of oximes in all three cell line 
suggest that HNK-102 and 2-PAM are equally good or HNK-
102 is better than 2-PAM. As far as CC50 of the compounds 
are concerned, again HNK-102 was found to be better than 
other oximes included in the study and comparable to 2-PAM. 
Similar observation were found when cells were analysed 
morphologically. We also validated our finding using trypan 
blue exclusion method for few experiments and observation 
was well corroborated with MTT assay suggesting membrane 
integrity of these cells. In our previous study HNK-102 was 
found to be better AChE reactivator as compared to 2-PAM8, 
but less toxicity of HNK-102 makes it better candidate drug in 
comparison to 2-PAM.  
The acute toxicity determination of any compound plays 
an important role in the designing of drug and its toxicological 
Figure 5. cell morphology: phase contrast microscopic 
observation of cells treated with different doses 
of oximes, showing dose-dependent morphological 
alterations. cells appeared   shrunken at dose of 
5 mg/ml of oximes (2-PaM, hnK-106 and hnK-
111). no change in the morphology was observed at 
0.5 mg/ml dose or lower; comparable to control 
group. (a) hela (b) hep G2 (c) heK 293.
(c)
(b)
(a)
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evaluation. The promising approach for the determination of 
acute toxicity in mammals is by using single dose of a chemical 
wherein lethality can be determined within 24 h. The lethality 
is expressed as LD50 and the mouse is one of the species used 
in these studies15. Toxicity of a compound involves absorption, 
distribution, metabolism of chemical and reaction with the 
targeted organ within the mammalian body. Hence, different 
exposure routes can have different bioavailability of a chemical 
which results in variable toxic effect within the same species.
Our study reports the acute toxicity of HNK series oximes 
and 2-PAM using different route of exposure in Swiss male 
albino mice (Table 1). The results showed that HNK-102 via 
intramuscular route showed the least toxicity (282.8 mg/Kg) 
among all the oximes. The rapid absorption of the drug via 
the muscles helps in easy entry of the drug into the circulation 
which can there by show the immediate effect. Also in the 
reported studies, HNK-102 showed far better Protection 
Index compared to 2-PAM against DFP and sarin poisoning 
via intramuscular route. Hence the choice of this drug via i.m. 
route is favaourable8,9. Similarly in case of intraperitoneal 
route, HNK-102 showed the least toxicity. In comparison to 
2-PAM ca. 3 times lower toxicity was shown by HNK-102 
via intraperitoneal route. Likewise via intravenous route, 
HNK-102 and 2-PAM was seen lesser toxic (90 mg/Kg and 
70.71 mg/Kg, respectively) compared to HNK-106 and HNK-
111. The large difference between the toxicity of HNK-102, 
HNK-106 and HNK-111 via i.p. and i.m. route underlay to the 
structural difference. This toxicity and structural difference can 
be explained on the following characteristics:
(i)  The presence of quaternary nitrogen
(ii)  The number of quaternary nitrogen
(iii) The number of oxime moiety and its position to the 
quaternary nitrogen atom and 
(iv) The nature of the linker. As shown, HNK-102 contains 
two carbons as a linker between the pyridine rings whereas 
HNK-106 and HNK-111 have 6 and 1 carbon linker chain 
respectively. 
Also, HNK-111 contains three pyridine ring compared to 
other oximes. The previous reports say that toxicity of alkenes, 
alkynes and -cyclo compounds are greater than alkanes 
group16. Hence, the presence of more alkyl and quaternary 
nitrogen group contributes to the higher toxicity by HNK-106 
and HNK-111.
As reported elsewhere, the bioavailability of the drug via 
intravenous and intraperitoneal route is almost similar16. Our 
in vitro data is satisfactorily correlating with data obtain by 
i.p. and i.v. route of administration. Being a small laboratory 
animal, the favourable choice of drug administration in mice is 
intra-peritoneal. But in actual condition of OP exposure among 
Humans, 2-PAM, 30 mg/Kg (1 g - 2 g) is administered by i.v. 
therapy over 15 min - 30 min, repeated in 1 h if necessary17. 
Likewise, in order to evaluate HNK-102 oxime via i.v. route, 
lethal toxicity was determined. Herein, the results also showed 
that HNK-102 is equivalent safe with 2-PAM, thus, favorable 
compound given via i.v. and i.p. route.
Although, metabolism or biotransformation both 
occur inside the body after oral or injection route, but there 
is difference in the rate of their occurrence. Through oral 
exposure, the chemical has to undergo first pass metabolism 
where it counter digestive enzymes, carried further into liver 
through portal vein and finally available for circulation in the 
body. As a consequence, the metabolised product (mostly the 
active chemical) from the liver, reached into the circulatory 
system in a very small amount. Whereas alternative routes like 
intramuscular and intravenous bypass the liver metabolism 
(first pass effect), results in the circulation of larger amount of 
compound in the body system. Henceforth, the drugs undergoing 
first pass metabolism and biotransformation in stomach can 
decrease the concentration of actual compound, leading to 
the difference of toxicity between oral and injection route. In 
our study, we compared LD50 of HNK oximes with standard 
oxime, 2-PAM. The results showed HNK-102, HNK-106 and 
HNK-111 offered acute toxicity 1130 mg/Kg, 1600 mg/Kg and 
> 565 mg/Kg, respectively. Similarly, 2-PAM showed 2520mg/
Kg of LD50 via oral (gavage) route. The plausible explanation 
to these findings is that the toxicity of the metabolites from 
the first pass effect if greater than their parent compound, the 
oral toxicity will be higher than the injection route. However, 
the results showed that all the reported oximes have lower oral 
toxicity compared to other routes of exposure. This clearly 
indicates that the HNK series oximes are safe and convenient 
for administration (comparable to 2-PAM) to be given via oral 
route against OP exposure. Moreover, the difference in lethal 
toxicity among HNK oximes and standard 2-PAM in oral route 
cannot only be attributed through the toxic metabolite of HNK 
oximes in the stomach. Gender (male and female Swiss mice) 
and species strain should also be considered in comparing the 
toxicity between these oximes. More studies in future related 
to the changes in liver and kidney markers, may depict the 
clear picture of their toxicity profile. 
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